# InSynchrony Ventures

InSynchrony Ventures is a Venture Capital based in Montreal, Canada.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Montreal, Canada
- **Region:** North America
- **Address:** 507 Place D'Armes, Suite 1101, Montreal, QC H2Y 2W8, Canada
- **Founded:** 2016
- **Assets under management:** Undisclosed
- **Website:** insynchronyventures.com
- **LinkedIn:** https://www.linkedin.com/company/insynchrony-ventures

## Regulatory record

- **Reports private funds:** No

## About

InSynchrony Ventures operates from Montreal, investing proprietary capital in early-stage biopharma, biotech, and therapeutic platforms. The firm is closely tied to InSymbiosis, a sister drug-development services business also founded by Dr. Dean Wenham, which gives the venture arm a built-in operational lens for scientific due diligence and post-investment support. The dual structure means portfolio companies get capital and a direct line into a contract research and development organization. The firm writes early-stage equity checks into Canadian life-science startups, concentrating on drug discovery, novel therapies, and platform biotech. Its model blends proprietary investing with hands-on industry knowledge drawn from InSymbiosis's ongoing client engagements. The geographic focus is Canada, though the firm has appeared alongside European co-investors such as High-Tech Gründerfonds in rounds like Germany-based Atriva Therapeutics. The commitment profile is direct, balance-sheet equity rather than a fund-of-funds or LP allocation. InSynchrony keeps a deliberately lean profile with no listed dedicated investment team beyond its founder and a business partner, Karl Rudolf Erlemann. Publicly tracked assets are modest — a commercial condo headquarters in Montreal and a reported sailing vessel — consistent with a principal-driven vehicle that doesn't run a large cost base. The absence of limited-partner fundraising rounds or separately managed accounts reinforces the self-funded, own-capital structure the firm describes. Structurally, the firm stands apart by operating as an investment company that shares origination tissue with a fee-for-service drug-development business. D. bench.

## Sectors

- Biotech & Pharma
- Digital Health

## People

- Dr. Dean Wenham — Founder and CEO
- Karl Rudolf Erlemann — Partner

## Questions

### Who runs investment decisions at InSynchrony Ventures?

Dr. Dean Wenham, the founder and CEO, drives investment decisions. He also leads InSymbiosis, the contract drug-development sister company, giving his venture decisions a built-in scientific backstop. Karl Rudolf Erlemann serves as a partner and is the only other named principal in public records.

### How does the firm's relationship with InSymbiosis affect its portfolio?

InSymbiosis is a contract research and drug-development services business founded by the same principal, Dr. Dean Wenham. InSynchrony portfolio companies can tap InSymbiosis for scientific and operational support, which means the venture capital and the fee-for-service lab work operate under the same leadership. This creates a due-diligence funnel: InSymbiosis sees early-stage therapeutic programs in its client work, and InSynchrony can invest in the most promising ones.

### Does InSynchrony Ventures invest outside Canada?

The firm's stated focus is Canadian, but publicly recorded co-investments include European rounds. It co-invested alongside Germany's High-Tech Gründerfonds in Atriva Therapeutics, a German biotech developing antiviral therapies. Still, the pipeline is anchored in Quebec and broader Canadian early-stage biopharma.

### What stage does InSynchrony Ventures target?

The firm targets early-stage opportunities, from pre-clinical discovery through early clinical-phase biotech and therapy platforms. The model is direct equity investment, not fund commitments or late-stage pre-IPO checks, which keeps its capital deployed close to the scientific risk window where InSymbiosis's lab expertise is most relevant.

## Related profiles

- [InsurTech.vc Management](https://altss.com/profile/insurtech-vc-management)
- [INT3](https://altss.com/profile/int3)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/insynchrony-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology